Intrance Medical Systems

Intrance Medical Systems, Inc. operates as a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for advanced Parkinson’s disease (APD). Established in 2018, the firm was an independent spin-out from the Sweden-based Lobsor Pharmaceuticals AB. The company's efforts are concentrated on bringing its lead product to markets including the U.S., Canada, South America, Japan, and Taiwan, where it holds all intellectual property and commercial rights.

The company's history is rooted in the extensive experience of its founders, Ulf Rosén and Roger Bolsöy. Both held key executive roles at companies like NeoPharma, Solvay, and AbbVie, where they were involved in the development and commercialization of a levodopa-carbidopa intestinal gel, a recognized therapy for APD. Leveraging this background, they founded Lobsor Pharmaceuticals and developed a patented gel formulation in 2013 to address unmet needs in APD treatment. This led to the creation of Intrance Medical Systems to handle commercialization in specific international markets. In September 2020, STADA's Britannia Pharmaceuticals acquired Lobsor, while Intrance retained its specified territorial rights.

Intrance Medical Systems is advancing a drug-device combination therapy, known in Europe as Lecigon®. This product is a fixed-dose gel formulation combining three active substances: levodopa, carbidopa, and entacapone. It is designed for continuous enteral infusion directly into the small intestine via a lightweight, wearable pump. This method of delivery bypasses the stomach, which can be beneficial as oral medication can become less effective in the later stages of Parkinson's due to issues like erratic gastric emptying. The addition of entacapone to the formula increases the bioavailability of levodopa, which allows for lower doses and the use of a smaller pump, weighing just 134 grams, enhancing patient convenience.

The company's business model centers on gaining regulatory approval and commercializing this specialized therapy for patients with advanced Parkinson's disease. Lecigon® has already been approved and is commercially available in several European countries, where it has seen positive market uptake. To fund its U.S. clinical development program, Intrance completed a Series A financing round in 2022, raising a total of $17 million, with notable investors including Erik Selin and Rutger Arnhult. The company has received FDA clearance for its Investigational New Drug (IND) application and is proceeding with its clinical trials in the United States.

Keywords: Parkinson's disease treatment, Levodopa-Carbidopa-Entacapone, enteral infusion, drug-device combination, neurodegenerative disorder therapy, Lecigon, continuous infusion pump, advanced Parkinson's, biopharmaceutical, clinical trials, dopamine metabolism, motor fluctuations, dyskinesia, CNS disorders, Ulf Rosén, Roger Bolsöy, intestinal gel, specialty pharma, wearable medical device, drug delivery system